Thermo Fisher grew revenue 10 percent as its lab and pharma end markets strengthened

Ten percent. That is how much Thermo Fisher Scientific grew revenue in the second quarter of 2026, to $11.99bn, in results the maker of laboratory instruments and reagents dated July 23 for the period ended June 27. Five percentage points of that growth was organic. The rest came from acquisitions and currency.

GAAP diluted earnings per share rose 9 percent to $4.68. Adjusted earnings per share, which the company prefers, rose 13 percent to $6.03. The adjusted operating margin widened to 22.8 percent, from 21.9 percent a year earlier.

Marc Casper, the chairman and chief executive, said the company's end markets continued to strengthen and that it kept gaining share, pointing to a run of new products including next-generation Orbitrap mass spectrometers shown at a mass-spectrometry conference during the quarter. The company held its updated full-year guidance back from the release. It said it would give the new numbers on its conference call at 8:30 in the morning, Eastern time.